HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis.

Abstract
Patients with cancer are at higher risk of severe coronavirus infectious disease 2019 (COVID-19), but the mechanisms underlying virus-host interactions during cancer therapies remain elusive. When comparing nasopharyngeal swabs from cancer and noncancer patients for RT-qPCR cycle thresholds measuring acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in 1063 patients (58% with cancer), we found that malignant disease favors the magnitude and duration of viral RNA shedding concomitant with prolonged serum elevations of type 1 IFN that anticorrelated with anti-RBD IgG antibodies. Cancer patients with a prolonged SARS-CoV-2 RNA detection exhibited the typical immunopathology of severe COVID-19 at the early phase of infection including circulation of immature neutrophils, depletion of nonconventional monocytes, and a general lymphopenia that, however, was accompanied by a rise in plasmablasts, activated follicular T-helper cells, and non-naive Granzyme B+FasL+, EomeshighTCF-1high, PD-1+CD8+ Tc1 cells. Virus-induced lymphopenia worsened cancer-associated lymphocyte loss, and low lymphocyte counts correlated with chronic SARS-CoV-2 RNA shedding, COVID-19 severity, and a higher risk of cancer-related death in the first and second surge of the pandemic. Lymphocyte loss correlated with significant changes in metabolites from the polyamine and biliary salt pathways as well as increased blood DNA from Enterobacteriaceae and Micrococcaceae gut family members in long-term viral carriers. We surmise that cancer therapies may exacerbate the paradoxical association between lymphopenia and COVID-19-related immunopathology, and that the prevention of COVID-19-induced lymphocyte loss may reduce cancer-associated death.
AuthorsAnne-Gaëlle Goubet, Agathe Dubuisson, Arthur Geraud, François-Xavier Danlos, Safae Terrisse, Carolina Alves Costa Silva, Damien Drubay, Lea Touri, Marion Picard, Marine Mazzenga, Aymeric Silvin, Garett Dunsmore, Yacine Haddad, Eugenie Pizzato, Pierre Ly, Caroline Flament, Cléa Melenotte, Eric Solary, Michaela Fontenay, Gabriel Garcia, Corinne Balleyguier, Nathalie Lassau, Markus Maeurer, Claudia Grajeda-Iglesias, Nitharsshini Nirmalathasan, Fanny Aprahamian, Sylvère Durand, Oliver Kepp, Gladys Ferrere, Cassandra Thelemaque, Imran Lahmar, Jean-Eudes Fahrner, Lydia Meziani, Abdelhakim Ahmed-Belkacem, Nadia Saïdani, Bernard La Scola, Didier Raoult, Stéphanie Gentile, Sébastien Cortaredona, Giuseppe Ippolito, Benjamin Lelouvier, Alain Roulet, Fabrice Andre, Fabrice Barlesi, Jean-Charles Soria, Caroline Pradon, Emmanuelle Gallois, Fanny Pommeret, Emeline Colomba, Florent Ginhoux, Suzanne Kazandjian, Arielle Elkrief, Bertrand Routy, Makoto Miyara, Guy Gorochov, Eric Deutsch, Laurence Albiges, Annabelle Stoclin, Bertrand Gachot, Anne Florin, Mansouria Merad, Florian Scotte, Souad Assaad, Guido Kroemer, Jean-Yves Blay, Aurélien Marabelle, Frank Griscelli, Laurence Zitvogel, Lisa Derosa
JournalCell death and differentiation (Cell Death Differ) Vol. 28 Issue 12 Pg. 3297-3315 (12 2021) ISSN: 1476-5403 [Electronic] England
PMID34230615 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2021. The Author(s).
Chemical References
  • DNA, Bacterial
  • Interferon Type I
  • RNA, Viral
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • COVID-19 (complications, virology)
  • Cohort Studies
  • DNA, Bacterial (blood)
  • Enterobacteriaceae (genetics)
  • Female
  • Humans
  • Interferon Type I (blood)
  • Lymphopenia (complications, virology)
  • Male
  • Micrococcaceae (genetics)
  • Middle Aged
  • Nasopharynx (virology)
  • Neoplasms (complications, diagnosis, mortality)
  • Pandemics
  • Prognosis
  • RNA, Viral (analysis)
  • SARS-CoV-2 (genetics)
  • Time Factors
  • Virus Shedding
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: